Prevenar 13 Gains China OK But Challenges Remain
Executive Summary
In a step that may boost flagging global sales, Pfizer’s big-selling pneumococcal vaccine Prevenar 13 has finally been approved in China, but the US giant still faces more than regulatory hurdles to get the product out into the market and accessible to patients.
You may also be interested in...
China Approves First HPV Vaccine But Can GSK Secure Its Lead?
After a decade-long wait, China has finally approved its first HPV vaccine, GSK's Cervarix, handing a lead to the UK-based firm over its US competitor Merck in the world’s second largest pharma market. But with Chinese companies also vying for a slice of the pie, the battle is just beginning, and pricing will be a key element.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.